Top 8 original publications from the CLII influencing policy and practice

(quoted metrics are as at 25 April 2017)
O'Donnell MR, Jarand J, Loveday M, Padayatchi N, Zelnick J, Werner L, Naidoo K, Master I, Osburn G, Kvasnovsky C, Shean K, Pai M, Van der Walt M, Horsburgh CR, Dheda K. High Incidence of Hospital Admissions with Multidrug Resistant and Extensively Drug Resistant Tuberculosis among South African Health Care Workers. Ann Internals Med. 2010. 153(8):516-22. (Senior author; IF = 19.384; cited 118 times since publication).
Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, Willcox P, John MA, Reubenson G, Govindasamy D, Wong M, Padanilam X, Dziwiecki A, van Helden PD, Siwendu S, Jarand J, Menezes CN, Burns A, Victor T, Warren R, Grobusch MP, van der Walt M, Kvasnovsky C. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. The Lancet. 2010. 375(9728):1798-807. (IF = 53.254; cited 180 times since publication).
Patel VB, Theron G, Lenders L, Matinyena B, Connolly C, Singh R, Coovadia Y, Ndung’u T, Dheda K. Quantitative PCR (GeneXpert MTB/RIF) for the diagnosis of tuberculous meningitis in HIV-infected patients from a high burden setting: a prospective study. PloS Medicine. 2013. 10(10):e1001536. (Senior author; IF = 13.585; cited 79 times since publication).
Pietersen E, Ignatius E, Streicher M, Mastrapa B, Padanilam X, Pooran A, Badri M, Lesosky M, van Helden P, Sirgel FA, Warren R, Dheda K. Incurable TB: Long-term outcomes in treatment failures with XDR-TB and resistance beyond XDR-TB from South Africa (a 10-year cohort study). The Lancet. 2014. 383(9924):1230-1239. Senior author; IF = 53.254; cited 66 times since publication).
Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K. Feasibility, accuracy and clinical impact of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised controlled trial. The Lancet. 2014. S0140-6736(13):62073-5. (Senior author; IF = 53.254; cited 220 times since publication).
Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, Mehta N, Calligaro G, Lombard CJ, Kadzirange G, Bandason T, Chansa A, Liusha N, Mangu C, Mtafya B, Msila H, Rachow A, Hoelscher M, Mwaba P, Theron G, Dheda K. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV- positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. The Lancet. 2016. 140-6736(15):01092-2. (Senior author; IF = 53.254; cited 52 times since publication).
Calligaro GL, Zijenah LS, Peter JG, Theron G, Buser V, McNerney R, Bara W, Bandason T, Govender U, Tomasicchio M, Smith L, Mayosi BM, Dheda K. The impact of new TB diagnostic technologies on community-based intensified case finding: a multi-centre randomised controlled trial. Lancet Infect Dis. 2016. 3099(16)30384-X. (Senior author; IF = 21.37, cited 0 times since publication).
Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lesosky M, Fennelly KP, te Riele J, Mastrapa B, Streicher EM, Dolby T, Abdallah AM, Ben-Rached F, Simpson J, Smith J, Gumbo T, van Helden P, Sirgel FA, McNerney R, Theron G, Pain A, Clark TG, Warren RM. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Infect Dis. 2017. 2600(16)30433-7. (IF = 25.148; cited 22 times since publication).

Key publications list

35 selected original publications (from a total of 190) are listed here (reviews and systematic reviews have been excluded). The journal impact factor and total Scopex and Google Scholar citation count as at 1 August 2016 has also been listed.
Dheda K, Shean K, Zumla A, Badri M, Streicher EM, ………Victor T, Warren R, Grobusch MP, van der Walt M, Kvasnovsky C. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010; 375(9728):1798-807. PMID: 20488525. (IF = 45.21; cited 146 times since publication).
O'Donnell MR, Jarand J, Loveday M, Padayatchi N, Zelnick J, Werner L, Naidoo K, Master I, Osburn G, Kvasnovsky C, Shean K, Pai M, Van der Walt M, Horsburgh CR, Dheda K.. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med. 2010; 153(8):516-22. PMID: 20956708. (Senior author; IF = 17.81, cited 81 times since publication).
Pietersen E, Ignatius E, Streicher M, Mastrapa B, Padanilam X, Pooran A, Badri M, Lesosky M, van Helden P, Sirgel FA, Warren R, Dheda K. Incurable TB: Long-term outcomes in treatment failures with XDR-TB and resistance beyond XDR-TB from South Africa (a 10- year cohort study). The Lancet. 2013; S0140-6736(13)62675-6. PMID: 24439237. (Senior author, IF = 45.21, cited 52 times since publication).
Patel VB, Theron G, Lenders L, Matinyena B, Connolly C, Singh R, Coovadia Y, Ndung'u T, Dheda K. Quantitative PCR (GeneXpert MTB/RIF) for the diagnosis of tuberculous meningitis in HIV-infected patients from a high burden setting: a prospective study. PloS Medicine. 2013; 10(10):e109536. PMID: 24167451. (Senior author, IF = 14.42, cited 43 times since publication).
Theron, G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K. Feasibility, accuracy and clinical impact of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised controlled trial. The Lancet. 2014; S0140-6736(13)62073-5. PMID: 24176144. (Senior author, IF = 45.21, cited 96 times since publication).
Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, Mehta N, Calligaro G, Lombard CJ, Kadzirange G, Bandason T, Chansa A, Liusha N, Mangu C, Mtafya B, Msila H, Rachow A, Hoelscher M, Mwaba P, Theron G, Dheda K. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV- positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet. 2016:140-6736(15)01092-2. PMID: 26970721. (Senior author, IF = 45.21, cited 2 times since publication).
Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy (HAART). J Infect Dis. 2004; 190:1670-6. PMID: 15478074. (IF = 6.34; cited 208 times since publication).
Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques. 2004; 37(1):112-4, 116, 118-9. PMID: 15283208. (IF = 1.60; cited 585 times since publication).
First published validated normalisation strategy for real time PCR applied to a commonly used TB antigen-driven human cell model system. The methodology has enabled accurate gene expression profiling of TB antigen-specific human cell culture systems and continues to be regularly cited.
Dheda K, Lalvani A, Miller RF, Scott G, Booth H, Johnson MA, Zumla A, Rook GA. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS. 2005; 9(17):2038-2041. PMID:16260914. (IF = 5.55 cited 117 times since publication).
Dheda K, Chang JS, Huggett JF, Bustin SA, Johnson MA, Rook GAW, Zumla A. Comparison of validated and unvalidated reference gene for normalisation of real-time RT-PCR assays. Analytical Biochem. 2005; 344(1):141-3. PMID: 16054107. (IF = 2.24; cited 505 times since publication).
Seminal paper, which proved that using inappropriate real-time PCR normalisations strategies can differentially and significantly impact gene expression signatures when using human cells. It is cited or used in several textbooks and guidelines including the MIQE reporting guidelines for the performance of real-time RT PCR.
Dheda K, Chang JS, Breen RA, Kim LU, Haddock JA, Huggett JF, Johnson MA, Rook GAW, Zumla A. In vivo and in vitro studies of a novel cytokine, Interleukin-4delta2, in Pulmonary Tuberculosis. Am J Resp Crit Care Med. 2005; 172(4):501-8. PMID: 16184029. (IF = 13.11; cited 56 times since publication).
Dheda K, van Zyl- Smit RN, Sechi LA, Badri M, Meldau R, Meldau S, Symons G, Semple L, Maredza A, Dawson R, Wainright H, Whitelaw A, Vallie Y, Raubenheimer P, Bateman ED, Zumla A. Utility of quantitative T cell responses versus unstimulated IFN-{gamma} for the diagnosis of pleural tuberculosis. Eur Respir J. 2009; 34(5):1118-26. PMID: 19386693. (IF =8.33; cited 61 times since publication).
Dheda K, van Zyl-Smit RN, Meldau R, Meldau, Symons G, Khalfey H, Govender N, Rosu V, Sechi LA, Maredza A, Semple PL, Whitelaw A, Wainright H, Badri M, Dawson R, Bateman ED, Zumla A. Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis. Thorax. 2009; (10):847-53. PMID: 19592392. (IF = 8.12; cited 45 times since publication).
van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Sechi LA, Bateman ED, Dheda K. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med. 2009; 180(1):49-58. PMID: 20041113. (Senior and corresponding author; IF = 13.11; cited 114 times since publication).
Dheda K, van Zyl-Smit RN, Sechi LA, Badri M, Meldau R, Meldau S, Symons G, Semple L, Maredza A, Dawson R, Wainright H, Whitelaw A, Vallie Y, Raubenheimer P, Bateman ED, Zumla A. Utility of quantitative T cell responses versus unstimulated IFN-{gamma} for the diagnosis of pleural tuberculosis. Eur Respir J. 2009; 34(5):1118-26. (IF = 8.33; cited 61 times since publication).
Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, Brunet L, van Zyl Smit R, Peter J, Green C, Badri M, Sechi L, Sharma S, Hoelscher M, Dawson R, Whitelaw A, Blackburn J, Pai M, Zumla A. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One. 2010; 5(3):e9848. PMID: 20352098. (IF = 3.54; cited 73 times since publication).
Patel VB, Singh R, Connolly C, Coovadia Y, Peer AK, Parag P, Kasprowicz V, Zumla A, Ndung'u T, Dheda K. Cerebrospinal T Cell Responses Aid the Diagnosis of Tuberculous Meningitis in a HIV and TB Endemic Population. Am J Respir Crit Care Med. 2010; 182(4):569-77. (Senior author; IF = 13.11; cited 45 times since publication).
Ling DI, Pai M, Davids V, Brunet L, Lenders L, Meldau R, Calligaro G, Allwood B, van Zyl- Smit R, Peter J, Bateman E, Dawson R, Dheda K. Are interferon-{gamma} release assays useful for active tuberculosis in a high-burden setting? Eur Respir J. 2011; 38(3):649-56. PMID: 21349910. (Senior author; IF = 8.33; cited 45 times since publication).
Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, Murray S, Dawson R, Whitelaw A, Hoelscher M, Sharma S, Pai M, Warren R, Dheda K. Evaluation of the Xpert(R) MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting. Am J Respir Crit Care Med. 2011; 84(1):132-40. PMID : 21493734. (Senior author; IF = 13.11; cited 145 times since publication).
Ling DI, Pai M, Davids V, Brunet L, Lenders L, Meldau R, Calligaro G, Allwood B, van Zyl-Smit R, Peter J, Bateman E, Dawson R, Dheda K. Are interferon-{gamma} release assays useful for active tuberculosis in a high-burden setting? Eur Respir J. 2011; 38(3):649-56. (Senior author; IF = 8.33; cited 45 times since publication).
Whitelaw A, Peter J, Sohn H, Viljoen D, Theron G, Badri M, Davids V, Pai M, Dheda K. Comparative cost and performance of LED-microscopy in HIV-TB co-infected patients. Eur Respir J. 2011; 38(6):1393-7. (Senior author; IF = 8.33; cited 14 times since publication).
Theron G, Pinto L, Peter J, Mishra HK, Mishra HK, van Zyl-Smit R, Sharma SK, Dheda K. The Use of an Automated Quantitative Polymerase Chain Reaction (Xpert MTB/RIF) to Predict the Sputum Smear Status of Tuberculosis Patients. Clin Infect Dis. 2011; 54(3):384-8. (Senior author; IF= 8.88; cited 28 times since publication).
Theron G, Pooran A, Peter J, van Zyl-Smit R, Mishra HK, Meldau R, Calligaro G, Allwood B, Sharma SK, Dawson R, Dheda K. Do adjunct TB tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? Eur Respir J. 2012; 40(1):161-8. (Senior author; IF= 8.33; cited 28 times since publication).
Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, Binder A, Meldau R, Hardy A, Dheda K. Diagnostic accuracy of a urine LAM strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012;7(7):e39966. (Senior author; IF= 8.33; cited 61 times since publication).
Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa? PLoS One. 2013; 8(1):e54587. PMID: 23349933. (Senior author; IF= 3.54; cited 49 times since publication).
Peter J, Theron G, Pooran A, Thomas J, Pascoe M, Dheda K. Comparison of two methods for acquisition of sputum samples for diagnosis of suspected TB in smear-negative and sputum-scare people: a randomised control trial. Lancet Respiratory Medicine. 2013;1(6):471-8. PMID: 24429245. (Senior author, IF = 15.32; cited 16 times since publication).
Theron G, Peter J, Meldau R, Khalfey H, Gina P, Matinyena B, Lenders L, Calligaro G, Allwood B, Symons G, Govender U, Setshedi M, Dheda K. Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax. 2013; 68(11):1043-51. (Senior author; IF= 8.12; cited 22 times since publication).
Peter J, Theron G, Pooran A, Thomas J, Pascoe M, Dheda K. Comparison of two methods for acquisition of sputum samples for diagnosis of suspected TB in smear-negative and sputum-scare people: a randomised control trial. Lancet Respiratory Medicine. 2013; 1(6):471-8. (Senior author, IF = 15.32; cited 16 times since publication).
Young BL, Mlamla Z, Gqamana PP, Smit S, Roberts T, Peter J, Theron G, Govender U, Dheda K, Blackburn J. The identification of tuberculosis biomarkers in human urine samples. Eur Respir J. 2014; 43(6):1719-29. (IF = 8.33, cited 5 times since publication).
Calligaro GL, Theron G, Khalfey H, Peter J, Meldau R, Matinyenya B, Dheda K. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial. Lancet Respiratory Medicine. 2015. 3 (8), 621-630. PMID: 26208996 (IF = 15.32, cited 3 times since publication).
Adams S, Ehrlich R, Baatjies R, van Zyl-Smit RN, Said-Hartley Q, Dawson R, Dheda K. Incidence of occupational latent tuberculosis infection in South African healthcare workers. Eur Respir J. 2015; (Senior author, IF = 8.33, cited 5 times since publication).
Hoff ST, Peter JG, Theron G, Pascoe M, Tingskov PN, Aggerbeck H, Kolbus D, Ruhwald M, Andersen P, Dheda K Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Respir J. 2016; 47(3):919-28. (Senior author, IF = 8.33, cited 2 times since publication).
Theron G, Venter R, Calligaro G, Smith L, Limberis J, Meldau R, Chanda D, Esmail A, Peter J, Dheda K. Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results? Clin Infect Dis. 2016; civ1223.(Senior author, IF = 8.88, cited 1 time since publication)